Esophageal cancer markers
View Patent ↗The present invention is directed to methods for diagnosing cancer in a subject. Morphologically normal epithelial cells of the esophagus are assayed for marker expression. Characteristic expression of the markers indicates the presence of cancer or the predisposition to cancer. A panel of eleven markers are particularly good at identifying cancer and the predisposition to cancer.
1. A method comprising:
testing a sample of morphologically normal esophageal epithelial cells of a human subject and determining expression of one or more genes, wherein said one or more genes comprises gravin;
determining a composite score of expression of the one or more genes;
comparing the composite score to predetermined values for esophageal cancer or predetermined values for increased risk of esophageal cancer; and
identifying the composite score as within the predetermined values for esophageal cancer or as within the predetermined values for increased risk of esophageal cancer if the composite score falls within the predetermined values.
2. A method comprising:
testing a sample of esophageal epithelial cells of a human subject and determining expression of one or more genes selected from the group consisting of gravin; H1 histone family, member 2 (H1 F2); H2A histone family, member L (H2AFL); H2B histone family, member C (H2BFC); keratin 8 (KRT8); progestin induced protein (DD5); H2A histone family, member O (H2AFO); transglutaminase 3 (TGF3); major histocopatibility complex, class II, DR alpha (HLA-DRA); mitotic checkpoint protein kinase BUB1B (BUB1B); and glutathione peroxidase 2 (gastrointestinal) (GPX2), wherein said one or more genes comprises gravin;
determining a composite score of expression of the one or more genes;
comparing the composite score to predetermined values for esophageal cancer or increased risk of esophageal cancer; and
identifying the composite score as within the predetermined values for esophageal cancer or predetermined values for increased risk of esophageal cancer if the composite score falls within the predetermined values.
3. A method comprising:
testing a sample of morphologically normal esophageal epithelial cells of a human subject and determining expression of one or more genes selected from the group consisting of gravin; H1 histone family, member 2 (H1F2); H2A histone family, member L (H2AFL); H2B histone family, member C (H2BFC); keratin 8 (KRT8); progestin induced protein (DD5); H2A histone family, member O (H2AFO); transglutaminase 3 (TGF3); major histocompatibility complex, class II, DR alpha (HLA-DRA); mitotic checkpoint protein kinase BUB1B (BUB1B); and glutathione peroxidase 2 (gastrointestinal) (GPX2), wherein said one or more genes comprises gravin;
determining a composite score of expression of the one or more genes;
comparing the composite score to predetermined values for esophageal cancer or increased risk of esophageal cancer; and
identifying the composite score as within the predetermined values for esophageal cancer or increased risk of esophageal cancer if the composite score falls within the predetermined values.
4. The method of claim 1 , 2 , or 3 wherein mRNA expression of the one or more genes is determined.
5. The method of claim 1 , 2 , or 3 wherein protein expression of the one or more gene is determined.
6. The method of claim 2 or 3 wherein a composite score of expression of eleven genes is determined.
7. The method of claim 2 or 3 wherein a composite score of expression of ten genes is determined.
8. The method of claim 2 or 3 wherein a composite score of expression of nine genes is determined.
9. The method of claim 2 or 3 wherein a composite score of expression of eight genes is determined.
10. The method of claim 2 or 3 wherein a composite score of expression of seven genes is determined.
11. The method of claim 2 or 3 wherein a composite score of expression of six genes is determined.
12. The method of claim 2 or 3 wherein a composite score of expression of five genes is determined.
13. The method of claim 1 , 2 , or 3 wherein a diet that decreases risk of neoplasia is recommended when presence or increased risk of esophageal cancer is identified.
14. The method of claim 1 , 2 , or 3 wherein the sample is obtained by endoscopy.
15. The method of claim 1 , 2 , or 3 wherein the sample is obtained by an inflatable balloon.
16. The method of claim 1 , 2 , or 3 wherein the sample is obtained by a sponge.
17. The method of claim 1 , 2 , or 3 wherein the human subject has diagnosed Barrett's esophagus.